|Articles|October 10, 2022

Massive Bio and Perthera.ai Announce Partnership

Massive Bio has announced a partnership with Perthera.ai. Perthera.ai’s ranked therapy recommendations will complement Massive Bio’s screening and analysis to aid more cancer patients in finding an appropriate clinical trial.

Read more about the partnership here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related Content

Where AI Has the Most Immediate Impact in Phase I Execution

ByAmber Hill, PhD,Andy Studna, Senior Editor

August 20th 2026

ACT Brief: AI Architecture and Model Ownership Due Diligence, FDA Framework for Generative AI Medical Devices, and Heidi Overton Nominated for FDA Commissioner

ByAndy Studna, Senior Editor

August 20th 2026

© JHVEPhoto - © JHVEPhoto - stock.adobe.com

FDA Seeks Public Input on Regulatory Framework for Generative AI-Enabled Medical Devices

ByAndy Studna, Senior Editor

August 19th 2026

How to Accelerate Trial Timelines Without Compromising Safety or Data Quality

ByAmber Hill, PhD,Andy Studna, Senior Editor

August 19th 2026

ACT Brief: Phase I Back-Office Automation Priorities, Early Phase Data Interpretation Under Capital Pressure, and Syneos AI Ecosystem Expansion

ByAndy Studna, Senior Editor

August 19th 2026

Trending on Applied Clinical Trials Online

Syneos Health Expands AI Ecosystem With Three New Platform Partnerships

FDA Seeks Public Input on Regulatory Framework for Generative AI-Enabled Medical Devices

ACT Brief: Phase I Back-Office Automation Priorities, Early Phase Data Interpretation Under Capital Pressure, and Syneos AI Ecosystem Expansion

One Clinical: Working Together to Advance Trial Collaboration

Avoiding Pitfalls When Every Patient Becomes a Readout